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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess whether blue-light filtering spectacle lenses impart effects on visual function, provide protection to the macula, or both. We
will also examine potential effects on the sleep-wake cycle.
B A C K G R O U N D
Description of the condition
The ubiquitous use of technology and increasing exposure to
modern lighting sources that emit relatively higher amounts of
blue light than traditional light sources (e.g. light emitting diodes
(LEDs) and compact fluorescent lamps (CFLs) (O’Hagan 2016)),
both in working and domestic environments, has raised questions
concerning the potential adverse effects of excessive exposure to
short-wavelength visible light. In terms of digital devices, use of
LED-backlit liquid crystal displays (LCDs) has been associated
with both symptoms of visual fatigue and changes to visual func-
tion, as quantified by a relative reduction in critical fusion fre-
quency (CFF), being the frequency at which an intermittent (flick-
ering) light stimulus appears to be in a complete steady stage to a
human observer (Isono 2013). In modern times, the range of eye
and vision-related symptoms associated with prolonged computer,
tablet, and e-reader use has been collectively defined as a multifac-
torial condition known as “Computer Vision Syndrome” (CVS)
(American Optometric Association 1995; American Optometry
Association 2018; Sheppard 2018).
Asthenopic symptoms, such as sore eyes, eye fatigue, headaches,
blurred vision, and dry eye, have been reported to affect up to 90%
of computer users (Rosenfield 2011).However, given themultifac-
torial nature of CVS, and that other ocular conditions (e.g. binoc-
ular vision disorders, uncorrected refractive error or presbyopia,
and tear film dysfunction) can elicit similar symptomatology, the
relative contribution of blue light to CVS is difficult to ascertain.
Despite the absence of a clear link between blue light and CVS, a
range of claims have beenmade in relation to the potential adverse
effects of blue-light emission from digital devices. This potential
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association forms the rationale for a variety of commercially-avail-
able interventions that reduce blue-light transmission to the eye
(e.g. spectacle lenses, downloadable software applications, filter at-
tachments to digital device screens, and changing internal settings
on electronic devices, such as ‘night mode’ settings).
With respect to potential effects on sleep, the increasing use of dig-
ital devices that emit relatively higher levels of short-wavelength
visible light than traditional incandescent light sources (e.g. LED-
backlit computer displays) has also raised concerns about the ef-
fect(s) of blue light (particularly evening exposure) on sleep. Such
effects on human chronobiology are considered to depend upon
the timing, duration, intensity, and spectral composition of the
light exposure (Czeisler 2013). Some epidemiological evidence
supports an association between evening use of electronic devices
and adverse sleep quality, altered circadian timing and reduced
daytime alertness (Chang 2015; Gamble 2014). However, exper-
imental investigation has also failed to demonstrate an associa-
tion between short-duration (one hour or less) screen use immedi-
ately prior to bedtime and altered sleep onset (Heath 2014). Some
evidence suggests disruptions to biological cycles and circadian
rhythm can potentially have adverse effects on a diverse range of
health parameters (Hatori 2017), including associations between
abnormal sleeping patterns and serious conditions such as sleep
disorders (Flo 2013), metabolic dysfunction (Karlsson 2001), and
cancer (Kolstad 2008). Understanding the role of blue-light filters
in reducing such outcomes thus has significant public health im-
plications.
In terms of potential effects onmacular health, themaintenance of
macular integrity is essential to normal visual function. In 2010,
it was estimated that 2.1 million people worldwide were blind,
and 6.0 million people were visually impaired, as a consequence
of macular disease (Jonas 2014). A leading cause of macular dis-
ease and adult vision impairment is age-related macular degenera-
tion (AMD) (Coleman 2008; Congdon 2004; Pascolini 2012), a
slowly progressive retinal degenerative condition that increases in
prevalence with age (Owen 2003; Wong 2014). About one-third
of individuals aged 80 years will show some clinical signs of AMD
(Klein 1992), with approximately 6% having late-stage AMD by
this age, and 20% at age 90 (Rudnicka 2012). Risk factors for
AMD include genetic factors (Klein 2005; Warwick 2017; Yang
2006), and tobacco smoking (Downie 2014; Thornton 2005). It
is currently unclear how other factors, including short-wavelength
light exposure, might contribute to the development of AMD,
progression of AMD, or both (Beatty 1999). Given there is cur-
rently no means for preventing AMD onset, nor a cure for the
disease, there is significant interest in novel methods for preserving
macular integrity through life.
Description of the intervention
Sunlight comprises of electromagnetic radiation ranging from ul-
traviolet (UV) to infrared (IR). UV radiation encompasses wave-
lengths from approximately 200 nanometres (nm) to 400 nm
(Youssef 2011). The visible light spectrum falls approximately be-
tween 400 nm to 760 nm, with ‘short-wavelength’ visible (blue)
light ranging from 400 nm to 500 nm (Mainster 2005).
Blue-light filtering, also termed “blue-blocking”, spectacle lenses
are ophthalmic lenses (generally prescribed in prescription glasses)
that are designed to selectively attenuate the transmissionofUV ra-
diation and short-wavelength visible light (Leung 2013; Mainster
2006). This is in contrast to standard spectacle lenses, which do
not filter blue light and provide varying degrees of inherent UV
protection depending on the lens material used (e.g. an uncoated
polycarbonate material will inherently provide relatively greater
UV attenuation than an uncoated CR-39 material lens).
Blue-light filtering spectacle lenses often contain a chromophore
that reduces or eliminates the amount of blue-light that reaches
the eye. Another approach involves coating the posterior and ante-
rior lens surfaces with an anti-reflection interference coating that
selectively decreases transmission of a portion of the blue-light
spectrum; the target range of wavelengths is typically 415 nm to
455 nm, corresponding to the region of the spectrum considered
to impart the highest risk of ocular damage (Boulton 2001).
A range of blue-light filtering spectacle lenses are currently com-
mercially available; examples include blueEast (Bonastar), Blue
control (Hoya), Crizal prevencia (Essilor), Dura vision/blue pro-
tect (Zeiss), Eyezen (Essilor), Gunnar (GUNNAROptics), Kodak
Total Blue (Signet Armolite Inc), and StressFree (Swisscoat).
How the intervention might work
By reducing the intraocular transmission of short-wavelength vis-
ible light, blue-light filtering spectacle lenses are hypothesised to
potentially impart a range of benefits, including improving visual
performance with digital device use, providing retinal protection
from light-induced damage, and minimising sleep and circadian
rhythm disruption associated with evening use of blue-light emit-
ting devices.
Despite the existence of studies that have investigated the appli-
cation of blue-light filtering spectacle lenses for reducing the signs
or symptoms of CVS, or both (Leung 2013; Lin 2017), the spe-
cific mechanism(s) underlying how these devices might impart
such benefit(s) are not known. The rationale for claims that blue
light-light filtering lenses attenuate CVS is based upon the premise
that modern digital devices (that emit relatively higher amounts
of blue light than traditional lighting sources) are frequently being
used for several hours per day and many device users experience
ocular discomfort. Given that there is a correlation between dis-
comfort glare sensitivity and brightness sensitivity with blue LEDs
(Kimura-Minoda 2011), a potential mechanism may involve a re-
duction in discomfort glare from a LED-backlit display; however,
there is no direct evidence to support this hypothesis.
With respect to the potential for intraocular light transmission to
pose an ocular hazard, retinal exposure to certain wavelengths of
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radiation is fortunately limited by the physiological absorbance
characteristics of the anterior eye. Ultraviolet wavelengths below
300 nm are absorbed by the cornea (Boettner 1962), and wave-
lengths between 300 nm and 400 nm are predominantly attenu-
ated by the crystalline lens (Boettner 1962; Norren 1974). With
age, the crystalline lens becomes relatively less transparent and
more yellow in colour, resulting in a reduction in the degree of reti-
nal transmission of short-wavelength visible light (400 nm to 500
nm), effectively acting as a natural blue-light filter (van Norren
2007). The change in lenticular absorbance of blue light occurs
exponentially (Weale 1988), such that by 50 years of age, only
20% of short-wavelength visible light reaches the retina (Dillon
2004). In this respect, it is unclear how blue-light filtering specta-
cle lenses might provide any benefit(s) in adults with a physiolog-
ically-yellowed lens due to age.
A population that theoretically may be relatively advantaged by
blue-light filtering spectacle lenses are individuals who have un-
dergone cataract surgery, with implantation of an intraocular lens
(IOL) that enables relatively more blue-light transmittance than
the aged crystalline lens (i.e. an UV-only filtering IOL) (Dillon
2004). There is experimental evidence from animal studies (Ham
1982; Noell 1966), and cell culture experiments (Sparrow 2004),
that demonstrates short-wavelength visible light exposure can in-
duce retinal phototoxicity. The mechanism involves retinal pho-
tochemical damage (Youssef 2011), as a result of reactive oxygen
species (ROS) generation, which induces protein oxidation and
lipid peroxidation (Boulton 2001). Whilst the retina has several
mechanisms of defence tomitigate ROS-dependent damage, these
processes become less efficient with age (Margrain 2004), thus po-
tentially rendering the ageing retina more vulnerable to phototox-
icity. As a result of their relatively high oxygen requirements, the
retinal pigment epithelium (RPE) and photoreceptors are consid-
ered most susceptible to blue light-induced photochemical dam-
age (Ham 1978; Ham 1984). This experimental evidence pro-
vides the basis for a hypothesis that blue light may also induce
retinal damage in humans and contribute to macular changes in
AMD. In this respect, spectacle lenses that attenuate retinal blue-
light exposure have been proposed to potentially be valuable for
providing macular protection, and reducing the risk of AMD de-
velopment progression (Beatty 1999; Bernstein 2010); a similar
rationale applies to the implantation of blue-light filtering IOLs,
following cataract surgery, however evidence for such a benefit is
currently lacking (Downie 2018).
The potential effects of blue light exposure on sleep quality and
circadian rhythm are also of relevance (Mainster 2006). The circa-
dian clock is regulated by the suprachiasmatic nucleus in the hy-
pothalamus, which controls melatonin secretion from the pineal
gland (Goel 2013). Daytime blue-light exposure can promote sub-
jective alertness by inhibiting the secretion of melatonin (Viola
2008). It follows that evening light exposure, particularly to short-
wavelength light (between 465 nm and 495 nm), may disrupt the
physiological circadian clock through a similarmechanism (Khalsa
2003; McIntyre 1989; Rahman 2014; Zeitzer 2000). This effect
has received particular attention owing to the extensive use of dig-
ital devices in the evening, close to bedtime, and the potential
impacts of this exposure on disrupting sleep quantity and quality
(Chinoy 2018). Based upon this rationale, it has been proposed
that limiting intraocular exposure to blue light in the evening,
through measures such as blue-light filtering spectacle filters and
using ‘night mode’ settings on devices, may be of value for miti-
gating these potentially negative effects on sleep.
Why it is important to do this review
There remains significant debate surrounding whether blue-
light filtering spectacle lenses have merit in ophthalmic practice
(Downie 2017). Although it is currently unknown how frequently
these lenses are being prescribed (in preference to standard spec-
tacles lenses), a range of marketing claims exist surrounding their
potential benefits. In particular, it has been proposed that blue-
light filtering spectacles may alleviate eye strain associated with
digital device use (Ide 2015; Lin 2017), improve sleep quality
(Ayaki 2016), and protect the retina, specifically the macula, from
phototoxicity (Blue Light Exposed 2015; Symes 2012). However,
in 2015, the UK Advertising Standards Authority (ASA) found
that an advertisement by an optical retailer promoting the use
of blue-light filtering spectacle lenses to “filter out harmful blue
light” represented misleading advertising “in the absence of ade-
quate substantiation” linking blue-light exposure to retinal dam-
age in clinical populations (McCormick 2016; UK Advertising
Standards Authority 2015).
There is currently a relative paucity of clinical evidence to sup-
port many claims surrounding the deleterious effects of blue-light
exposure. Although ocular discomfort symptoms have been long-
associated with computer and video display terminal use (Smith
1981; Ustinaviciene 2006), the relative contribution of blue light
per se (rather than other potential causative factors, such binocu-
lar vision anomalies, postural factors and/or tear film dysfunction)
remains unclear.
In terms of potential effects on sleep, a recent systematic review and
meta-analysis (which allowed the inclusion of randomised con-
trolled trials (RCTs), cohort, and cross-sectional studies) reported
a significant association between portable screen-based media de-
vice (e.g. cell phone and table devices) access or use, in the sleep
environment, and reduced sleep outcomes (including inadequate
quantity, poor quality and excessive daytime sleepiness) in children
(Carter 2016). However, as acknowledged by the authors of the
review, the certainty of the evidence (assessed using the GRADE
approach) was judged as low due to a necessary reliance on non-
randomised studies (Carter 2016). Thus there is the potential for
the true effect to be substantially different from the reported effect
estimate.
Concerning the potential effect(s) of blue-light filtering spectacles
in imparting macular protection, 10 out of the 12 major popula-
3Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
tion-based studies that sought to determine whether there was a re-
lationship between light exposure and AMD did not report a pos-
itive association (Mainster 2006). Similarly, it is unclear whether
age-related cataract surgery, in which removal of the aged crys-
talline lens (which acts as a physiological blue filter) and its replace-
ment with a non-blue light filtering IOL, is a risk factor for AMD
development, AMD progression, or both. Although some studies
have reported a positive association (Klein 1998; Liu 1989), oth-
ers have found an absence of relationship with respect to the risk
of developing late-stage AMD in individuals with earlier stages of
the condition (Baatz 2008; Chew 2009). Notably, observational
studies have important methodological limitations, including the
potential influences of bias and confounding, which limit the in-
terpretation of these findings.
Given the relative attenuation of short-wavelength visible light
with a blue-light filter, any potentially undesirable effects on visual
function, in particular alterations to colour discrimination, also
need to be considered. In the context of blue-light filtering IOLs,
a recent systematic review by Downie 2018 concluded that, due
to a paucity of studies, it is currently unclear whether these devices
affect colour vision relative to non-blue light filtering IOLs. The
status of the evidence relating to blue-light filtering spectacle lenses
also requires clarification.
Consequently, current limitations in the scientific literature em-
phasise an urgent need to clarify whether blue-light filtering spec-
tacles affect eye strain associated with digital device use, visual per-
formance, sleep, andmacular health (Lawrenson 2017). A rigorous
systematic review, considering the best-available RCT evidence, is
essential to objectively evaluate the relative appropriateness of pre-
scribing blue-light filtering ophthalmic lenses for these purposes.
The relative benefits and potential harms of these devices also need
to be considered. This knowledge has the capacity to inform clini-
cal practice guidelines relating to the prescription of blue-light fil-
tering spectacle lenses, and thus is of strong relevance to clinicians,
patients, researchers, and the broader ophthalmic community. We
expect that this systematic review may also identify important ar-
eas for future research in the field, to fill any evidence gaps.
O B J E C T I V E S
To assess whether blue-light filtering spectacle lenses impart effects
on visual function, provide protection to the macula, or both. We
will also examine potential effects on the sleep-wake cycle.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs).
Types of participants
Participants in the RCTs will be adults (i.e. at least 18 years of
age).
Types of interventions
We will include RCTs that compared blue-light filtering spectacle
lenses with non-blue-light filtering spectacle lenses. We will ex-
clude studies that investigated blue-light filtering spectacle lenses
in combination with any other intervention, unless the same in-
tervention was also used in the comparator group.
Types of outcome measures
Primary outcomes
The primary outcomes,measured at onemonth of follow-up (with
an acceptable follow-up range of between two weeks and three
months), will be:
• Change in visual fatigue or discomfort, measured using a
questionnaire or visual analogue scale;
• Change in CFF, measured in Hertz (Hz).
Secondary outcomes
We will consider the following secondary outcomes:
• change in best-corrected visual acuity (BCVA), with or
without (disability) glare, measured in logMAR;
• change in contrast sensitivity, measured in log contrast
sensitivity, with and without (disability) glare;
• change in discomfort glare, measured using a questionnaire
(e.g. de Boer scale) or objectively (e.g. electromyogram);
• proportion of eyes, or individuals (as determined by the
unit of analysis), with a finding of a pathological structural
change at the macula, detected by clinical observation, optical
coherence tomography (OCT) or retinal fundus photography;
• change in colour discrimination, considered as the standard
mean difference for panel tests (e.g. Farnsworth D15 and 100-
hue) or the number of errors on plate tests (e.g. Ishihara),
measured under photopic, mesopic, or scotopic conditions;
• daytime alertness, considered as the proportion of
participants who had reduced daytime alertness, measured using
a subjective scale;
• change in serum melatonin levels, measured in pg/mL;
• sleep quality, measured using questionnaires or rating scales;
• overall patient satisfaction with their visual performance,
measured using questionnaires or rating scales.
4Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The follow-up period for secondary outcomes will be measured
at one month (with an acceptable range of two weeks to three
months), with the exception of the ‘proportion of eyes, or indi-
viduals, with a finding of a pathological structural change at the
macula’, which will be measured at 12 months (with an acceptable
range of six to 24 months).
Adverse effects
We will tabulate any ocular or systemic adverse effects, as reported
in the included trials.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases. There will be no language or
publication year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Trials Register) in the Cochrane Library (latest issue) (Appendix
1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• LILACS (1982 to present) (Appendix 4);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch)
(Appendix 5);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( www.clinicaltrials.gov) (Appendix 6);
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( www.who.int/ictrp)
(Appendix 7).
Searching other resources
Wewill undertake additional searching, using the bibliographies of
included RCTs, to identify any other potentially relevant studies.
Data collection and analysis
Selection of studies
We will adopt a two-stage process to identify relevant trials.
First, two review authors will independently evaluate the title and
abstract results from the search strategies, to identify studies po-
tentially suitable for inclusion. We will obtain full-text articles of
records that at least one review author judges as relevant, or pos-
sibly relevant. Two review authors will independently assess every
full-text article and assess its suitability for inclusion in the review,
according to the Criteria for considering studies for this review.
We will resolve any disagreements in classification by discussion
and consensus between the two review authors; if required, we will
consult a third review author for a final judgement with respect to
eligibility.
For records where more information is considered necessary to
determine eligibility, we will contact the trial authors by email to
request this information. If we do not receive a response within
four weeks, we will use the information provided within the full-
text article to assess eligibility. We will provide details relating to
the reason for excluding studies that progress to the full-text review
stage, in a ‘Characteristics of excluded studies’ table.
Data extraction and management
Two review authors will independently extract key study data (de-
tailed in Appendix 8) using Covidence (Covidence). In brief, rel-
evant information to capture will include details of the study de-
sign, country, setting, participant characteristics, number of par-
ticipants, outcomes, results, and any other relevant information
(e.g. funding sources, declarations of interest). Wherever possible,
we will extract quantitative data for pre-specified outcomes. The
two review authors will resolve any discrepancies in data extraction
by discussion to reach consensus; if necessary, they will consult a
third review author who will adjudicate. After reaching consen-
sus in Covidence, one review author will export the collated data
into Cochrane’s Review Manager 5 (RevMan 5) software (Review
Manager 2014). A second review author will independently verify
the data.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias in
each of the included trials using the guidelines in Chapter 8 of the
Cochrane Handbook for Systematic Review of Interventions (Higgins
2017). We will evaluate risk of bias in the following domains:
• selection bias (random sequence generation and allocation
concealment);
• performance bias (masking of participants and personnel);
• detection bias (masking of outcome assessment);
• attrition bias (incomplete outcome data);
• reporting bias (selective reporting of outcomes);
• other bias (funding source, other conflicts of interest).
Two review authors will judge the risk of each bias in each of the
included studies as: (i) low risk, (ii) unclear risk (due to either
lack of information or uncertainty over the potential for bias) or
(iii) high risk. We will resolve any disagreements in risk of bias
assessment by consensus.
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Measures of treatment effect
We will undertake the data analyses according to the approach
described in Chapter 9 of the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2017).
For continuous outcomes, we will extract information on the
change, from baseline, in means (and standard deviations (SDs) of
changes) of the outcome measures for the intervention and com-
parator groups at the specified follow-up period(s). Where mea-
sures of change are not reported, we will extract the mean and SD
values of the outcome for the intervention and comparator groups
at the specified follow-up period(s). We will express treatment ef-
fects as the mean difference (MD), with 95% confidence intervals
(CIs), between the intervention and comparator groups.
For the dichotomous outcome (i.e. proportion of participants who
had reduced daytime alertness), we will compare data between
the intervention and comparator groups and will present it as risk
ratios (RRs) with 95% CIs.
Unit of analysis issues
For the purpose of this review, the unit of analysis will be the study
participant.
Given the nature of spectacles, trials are predicted to randomise
individuals (rather than eyes) to the intervention and comparator.
Although paired-eye studies are unlikely, we will include these if
identified.
It is possible that for some outcomes (e.g. BCVA, contrast sen-
sitivity) data may be collected from both eyes. Where the study
collected data onmore than one eye per participant, we will follow
guidelines for clustering or paired-eye design described in Chapter
16 of theCochraneHandbook for Systematic Reviews of Interventions
(Higgins 2011). If only one eye per person is included in the trial,
there will not be a unit of analysis issue, and we will document how
the eye was selected (if specified in the study report). If individual
participants are randomly allocated to the intervention but data
from both eyes are included and reported, we will analyse this as
‘clustered data’ (i.e. with an adjustment for within-person correla-
tion); if necessary, we may contact the trial investigators for more
information to perform this analysis. For the outcome measure
relating to pathological structural change at the macula, we will
report either the proportion of eyes (for paired-eye studies) or the
proportion of participants with structural changes in one or both
eyes (for trials randomising individuals).
Dealing with missing data
For studies that have missing outcome data (e.g. omitted standard
deviations or standard errors), we will attempt to contact the trial
authors via email for the necessary information. If we donot receive
a response within four weeks, or if the trial authors are unable to
provide this information, we will use the information available in
the full-text publication.
If feasible, we will undertake an intention-to-treat (ITT) analy-
sis. We will use imputed data if the trial authors provide it using
a robust method; however we will not directly impute data our-
selves. If ITT data are not provided in the included trials, we will
undertake an available case analysis, which assumes that data are
missing at random. We will assess if this assumption is reasonable
by collecting data on the number of participants excluded or lost
to follow-up, and the reasons for loss to follow-up by treatment
group, from each included study (as reported).
Assessment of heterogeneity
We will assess trials for heterogeneity using the recommendations
outlined in Chapter 9 of the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2017). We will examine clinical
and methodological heterogeneity between trials by considering
differences in RCT design, participant characteristics at baseline
(e.g. age, gender, eligibility criteria, etc.), and the risk of bias.
Statistical heterogeneity between studies will be quantified using
the I2 statistic (Higgins 2003). We will interpret an I2 statistic of
60% or more to be at risk of moderate heterogeneity (Ng 2014).
In identifying and measuring heterogeneity, we will consider the
magnitude and direction of effects of individual trials, and the
strength of evidence for heterogeneity (using a P value < 0.10,
from the Chi2 test as an indicator of significant heterogeneity).
Assessment of reporting biases
We will examine the risk of reporting bias (due to selective report-
ing of outcomes) by comparing the outcomes defined in the trial
protocol (where available) or clinical trial registry, with those in
the full-text publication(s).
If there are 10 or more studies to include in a meta-analysis, we
will assess for any potential publication bias using a funnel plot.
We will interpret any asymmetries in the funnel plot in association
with the trial characteristics, in consideration of factors such as
sample size.
Data synthesis
We will perform meta-analyses for the primary and secondary
outcomes, if appropriate. If fewer than three trials are included in
the meta-analysis, we will use a fixed-effect model; otherwise we
will use a random-effects model.
If we determine there to be inconsistency between trial findings
(e.g. effects in different directions, or I2 statistic more than 60%,
or a Chi2 test P value < 0.10), such that a pooled result may not
provide an appropriate summary of the findings, we will describe
the pattern of individual trial results. If there is statistical hetero-
geneity but all of the effect estimates are in a consistent direction,
such that a pooled estimate would seem to provide an appropriate
summary of the individual RCT results, we will pool data in a
meta-analysis.
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If we deem a meta-analysis to be inappropriate, we will provide a
descriptive or tabulated results summary.
Subgroup analysis and investigation of heterogeneity
If a sufficient number of trials (considered two trials per subgroup
or more) are available, we will perform a subgroup analysis for
factors that could potentially affect outcomes. Specifically, we will
assess for the potential effects of: participant age (less than 40 years
versus 40 years or older), degree of blue-light attenuation imparted
by the blue-light filtering lens product (‘high’ block versus ‘low’
block), and extent of digital device use (less than two hours per
day versus two or more hours per day).
Sensitivity analysis
If a sufficient number of trials meet the inclusion criteria of the
review, we will perform a sensitivity analysis for the primary out-
come measures, to assess for the effects of excluding trials that:
(i) we judged to have a high risk of bias due in the domains of
allocation concealment or lack of masking (or participants and
personnel, or outcome assessors), (ii) are unpublished, and (iii)
were funded by industry.
Summary of findings
We will create a ‘Summary of findings’ table summarising the re-
sults of the analyses, provided sufficient data are available, using
the approach described in Chapter 11 of the Cochrane Handbook
for Systematic Reviews of Interventions (Schünemann 2017). The
GRADE Working Group approach will be adopted to grade the
certainty of evidence. Outcomes, measured between the interven-
tion and control groups, will include:
• change in visual fatigue or discomfort;
• change in CFF;
• change in BCVA, with or without (disability) glare;
• proportion of eyes, or individuals, with a finding of
pathological structural change at the macula;
• change in colour discrimination;
• sleep quality;
• proportion of participants with adverse events with a
probable causal link with the study intervention.
For all outcomes, we will measure the change from baseline at one
month of follow-up (with an acceptable range of twoweeks to three
months), with the exception of the ‘proportion of participants
with adverse events with a probable causal link with the study
intervention’ and the ‘proportion of eyes, or individuals, with a
finding of a pathological structural change at themacula’, whichwe
will assess at the follow-up period(s) reported by the trial authors.
A C K N OW L E D G E M E N T S
Cochrane Eyes and Vision (CEV) will create and execute the elec-
tronic search strategies. The Methods section of this protocol in-
cludes some text from a standard template prepared by CEV. We
thank Sharon Bentley for her comments on the protocol and Jen-
nifer Evans and Anupa Shah for their assistance during protocol
development.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Eyeglasses] this term only
#2 (spectacle* or eyeglasses or glasses)
#3 #1 or #2
#4 MeSH descriptor: [Filtration] this term only
#5 blue near/2 light*
#6 blue near/3 filter*
#7 blue near/3 block*
#8 violet near/3 filter*
#9 blue light near/2 (emission* or transmission*)
#10 (short next wavelength near/2 light)
#11 UV near/2 (protect* or attenuat*)
#12 (blueEast or “Blue control” or “Crizal prevencia” or “Dura vision” or Eyezen or Gunnar or “Kodak Total Blue” or StressFree)
#13 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 #3 and #13
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. Eyeglasses/
14. (spectacle$ or eyeglasses or glasses).tw.
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15. or/13-14
16. Filtration/
17. (blue adj2 light$).tw.
18. (blue adj3 filter$).tw.
19. (blue adj3 block$).tw.
20. (violet adj3 filter$).tw.
21. (blue light adj2 (emission$ or transmission$)).tw.
22. (short adj1 wavelength adj2 light).tw.
23. (UV adj2 (protect$ or attenuat$)).tw.
24. (blueEast or “Blue control” or “Crizal prevencia” or “Dura vision” or Eyezen or Gunnar or “Kodak Total Blue” or StressFree).tw.
25. or/16-24
26. 15 and 25
27. 12 and 26
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp spectacles/
34. (spectacle$ or eyeglasses or glasses).tw.
35. or/33-34
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36. blue light/
37. (blue adj2 light$).tw.
38. (blue adj3 filter$).tw.
39. (blue adj3 block$).tw.
40. (violet adj3 filter$).tw.
41. (blue light adj2 (emission$ or transmission$)).tw.
42. (short adj1 wavelength adj2 light).tw.
43. (UV adj2 (protect$ or attenuat$)).tw.
44. (blueEast or “Blue control” or “Crizal prevencia” or “Dura vision” or Eyezen or Gunnar or “Kodak Total Blue” or StressFree).tw.
45. or/36-44
46. 35 and 45
47. 32 and 46
Appendix 4. LILACS search strategy
(tw:(spectacles or glasses or eye glasses)) AND (tw:(blue light or blue filter or blue blocking or violet
filter or UV protection))
Appendix 5. ISRCTN search strategy
(spectacles OR glasses OR eye glasses) AND (blue light OR blue filter OR blue blocking)
Appendix 6. ClinicalTrials.gov search strategy
(spectacles OR glasses OR eye glasses) AND (blue light OR blue filter OR blue blocking)
Appendix 7. WHO ICTRP search strategy
spectacles AND blue light OR glasses AND blue light OR eyeglasses AND blue light OR spectacles AND blue
filter OR glasses AND blue filter OR eyeglasses AND blue filter OR spectacles AND blue blocking OR glasses
AND blue blocking OR eyeglasses AND blue blocking
Appendix 8. Data on study characteristics
Primary items Other items
Methods
Study design e.g. parallel group RCT, paired-eye RCT,
cluster RCT, cross-over RCT, or other de-
sign
Exclusions after randomisation
Losses to follow-up
How missing data were handled e.g. avail-
able case analysis, imputation methods
Reported power calculation (Y/N), includ-
ing sample size and power
Unusual study design/issues (as required)
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(Continued)
Unit of randomisation/unit of analysis e.g. one eye included in study, two eyes in-
cluded in study, both eyes received same
treatment, or two eyes included in study,
eyes received different treatments
Participants
Country Setting
Baseline characteristics
Comparison of study groups at baselineTotal number of participants
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n = )
Comparator (n = )
Descriptionof interventions (e.g., spectacle
lens name and manufacturer)
Frequency with which the intervention
(spectacle lenses) were worn over the trial
duration
Outcomes
Primary and secondary outcomes, as de-
fined in the study report
Details of outcomes
Length of follow up and intervals at which
outcomes were assessed
Planned/actual length of follow-up
Notes
Date conducted Specify dates of recruitment of participants Trial registration details
Full study name: (if applicable)
Corresponding author’s name and contact
details (email, mailing address)
Were trial investigators contacted? (Any rel-
evant details)
Funding sources
Declaration of interest
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